VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
MGTX
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
MGTXMeiraGTx Holdings plc
$13.89$1.3B
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders

MGTX logoMeiraGTx Holdings plc(MGTX)Earnings, Financials & Key Ratios

MGTX•NASDAQ
$13.89
Price updated Jul 6, 2026
SectorHealthcareIndustryBiotechnologySub-IndustryCell and Gene Therapy Developers
AboutMeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited blindness, as well as Xerostomia following radiation treatment for head and neck cancers; degenerative diseases; neurodegenerative diseases, such as amyotrophic lateral sclerosis; and Parkinson's diseases. Its programs in clinical development include Phase 1/2 clinical stage programs in Achromatopsia, X-Linked Retinitis Pigmentosa, RPE65-deficiency, and radiation-induced Xerostomia, as well as Parkinson's program. The company also focuses on initiating a clinical program in xerostomia related to Sjogren's syndrome and have preclinical programs in neurodegenerative diseases. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop regulatable gene therapy treatment using the company's proprietary riboswitch technology. MeiraGTx Holdings plc was incorporated in 2015 and is based in New York, New York.Show more
  • Revenue$81M+144.6%
  • EBITDA-$106M+30.0%
  • Net Income-$114M+22.7%
  • EPS (Diluted)-1.42+33.0%
  • Gross Margin94.05%+229.9%
  • EBITDA Margin-130.2%+71.4%
  • Operating Margin-130.2%+73.6%
  • Net Margin-140.31%+68.4%
  • ROE-368.19%-156.6%

MGTX Price & Volume

MeiraGTx Holdings plc (MGTX) stock price & volume — 10-year historical chart

Loading chart...

Milestone Dependency Masks Persistent Operational Capital Erosion

Investment Thesis • Updated 2026Q1

VerdictNegative
Growth:Mixed
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Clinical Milestone Revenue Dependency

Key Thesis Takeaways

  • MeiraGTx operates a high-risk, asset-heavy business model characterized by extreme revenue volatility tied to non-recurring collaboration milestones rather than sustainable commercial demand.
  • The company faces significant solvency pressure, evidenced by a shift to negative equity of $58.1 million and a compressed current ratio of 0.55 as of 2026Q1.
  • Investors should remain cautious as the firm's reliance on internal manufacturing infrastructure and persistent clinical development burn necessitates ongoing, potentially dilutive, capital raises to maintain operations.

Verdict Logic

the company's current ratio of 0.55 and negative equity of $58.1 million indicate severe liquidity constraints that outweigh the potential upside of its clinical development pipeline.

MGTX Growth Metrics

MeiraGTx Holdings plc (MGTX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years-
5 Years39.22%
3 Years72.27%
TTM131.13%

Profit CAGR

10 Years-
5 Years-
3 Years-
TTM27.97%

EPS CAGR

10 Years-
5 Years-
3 Years-
TTM36.21%

Return on Capital

10 Years-92.29%
5 Years-52.6%
3 Years-63.14%
Last Year-64.06%

MGTX Recent Earnings

MeiraGTx Holdings plc (MGTX) EPS & revenue vs analyst estimates — last 4 quarters

Full history →
●Beat EPS 3/12 qtrs (25%)●Beat Revenue 4/12 qtrs (33%)
Q2 2026Latest
May 14, 2026
Metric
Actual
Est
EPS
$0.57-32.6%
$0.43
Rev
$293,000-98.3%
$17M
Q2 2026
Mar 26, 2026
Metric
Actual
Est
EPS
$0.19+131.7%
$0.60
Rev
$75M+5115.3%
$1M
Q4 2025
Nov 13, 2025
Metric
Actual
Est
EPS
$0.62-24.0%
$0.50
Rev
$410,000-89.4%
$4M
Q3 2025
Aug 14, 2025
Metric
Actual
Est
EPS
$0.48+7.7%
$0.52
Rev
$4M-43.1%
$6M
QuarterDateEPS (Act vs Est)Revenue (Act vs Est)
Q2 2026LatestMay 14, 2026
$0.57vs $0.43-32.6%
$293,000vs $17M-98.3%
Q2 2026Mar 26, 2026
$0.19vs $0.60+131.7%
$75Mvs $1M+5115.3%
Q4 2025Nov 13, 2025
$0.62vs $0.50-24.0%
$410,000vs $4M-89.4%
Q3 2025Aug 14, 2025
$0.48vs $0.52+7.7%
$4Mvs $6M-43.1%
Based on last 12 quarters of dataView full earnings history →

Latest MGTX News

Recent stock market news and headlines for MeiraGTx Holdings plc (MGTX)

Seeking Alpha·Jun 29, 2026
MeiraGTx: The Market Is Missing The Manufacturing Pivot

MeiraGTx is evolving into a late-stage, manufacturing-enabled genetic medicine company with multiple near-term regulatory catalysts. MGTX's robust manufacturing infrastructure and targeted therapies, such as Bota-vec and AAV2-hAQP1, position it for commercial inflection without mass-market commercialization burdens. Recent equity raise and anticipated milestone payments extend MGTX's cash runway through 2H 2028, supporting execution of late-stage programs.

Peers Comparison

Key metrics vs top competitors for MeiraGTx Holdings plc (MGTX)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
MGTX logoMGTXMeiraGTx Holdings plcCurrent
$13.89$1.29B-9.78144.57%-140.31%-368.19%—
ADVM logoADVMAdverum Biotechnologies, Inc.
$4.36$96.26M-0.66-72.22%———
OCGN logoOCGNOcugen, Inc.
$1.49$504.4M-6.488.83%-1605.22%-127987.5%—
EDIT logoEDITEditas Medicine, Inc.
$3.65$357.36M-2.0325.39%-281.59%-677.39%—
CRSP logoCRSPCRISPR Therapeutics AG
$61.89$5.97B-9.57-89.97%-13856.54%-30.88%—
NTLA logoNTLAIntellia Therapeutics, Inc.
$17.84$2B-4.6816.92%-597.04%-57.27%—

Compare MGTX vs Peers

MeiraGTx Holdings plc (MGTX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs ADVM

Most directly comparable listed peer for MGTX.

Scale Benchmark

vs REGN

Larger-name benchmark to compare MGTX against a more recognizable public peer.

Peer Set

Compare Top 5

vs ADVM, OCGN, EDIT, CRSP

MGTX SEC Filings & Documents

MeiraGTx Holdings plc (MGTX) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

May 14, 2026·SEC

Material company update

Apr 24, 2026·SEC

Material company update

Apr 16, 2026·SEC

10-K Annual Reports

4
FY 2026

Mar 30, 2026·SEC

FY 2025

Mar 13, 2025·SEC

FY 2024

Mar 15, 2024·SEC

10-Q Quarterly Reports

6
FY 2026

May 14, 2026·SEC

FY 2025

Nov 13, 2025·SEC

FY 2025

Aug 14, 2025·SEC

Get notified when MGTX posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

MGTX Frequently Asked Questions

MeiraGTx Holdings plc (MGTX) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
What is MeiraGTx Holdings plc's revenue?

MeiraGTx Holdings plc (MGTX) reported $79.8M in revenue for fiscal year 2025.

How fast is MeiraGTx Holdings plc growing?

MeiraGTx Holdings plc (MGTX) grew revenue by 144.6% over the past year. This is strong growth.

Is MGTX profitable?

MeiraGTx Holdings plc (MGTX) reported a net loss of $120.5M for fiscal year 2025.

Dividend & Returns
What is MGTX's return on equity?

MeiraGTx Holdings plc (MGTX) has a return on equity (ROE) of -368.2%. Negative ROE indicates the company is unprofitable.

What is MeiraGTx Holdings plc's free cash flow?

MeiraGTx Holdings plc (MGTX) had negative free cash flow of $2.3M in fiscal year 2025, likely due to heavy capital investments.

What if you invested $1,000 in MGTX back in 2016?

Total return calculator · dividends reinvested · 10+ years of data

See returns →